Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06408168
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-04-30
Brief Title:
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor REPLOT Trial
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-10-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-30
First Submit QC Date:
May 6 2024
Study First Post Date:
2024-05-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-16
Last Update Post Date:
2024-06-28
Last Update Post Date Type:
ACTUAL